You are here: Profiles / Michael R. Goldberg (List of Publications)








1.            Kutscher, A.H., Goldberg, M., eds., Caring for the Dying Patient and his Family:  A model for medical education-medical center conferences.  Health Sciences Publishing Co., New York, 1973.


2.            Goldberg, M.R., A pharmacologic study of the canine lateral saphenous vein, Ph.D. Dissertation, Tulane Graduate School, May 1976.


3.            Kutscher, A.H., Goldberg, M.R.,, eds., Pharmacology for the Dental Hygienist:  Lea and Febiger, 1982.




1.            Agents which affect the cardiovascular system.  In:  Pharmacology for the Dental Hygienist.  Ed. A. H. Kutscher, Lea and Febiger, 1982.


2.            Autonomic drugs.  In:  Pharmacology for the Dental Hygienist. Ed. A.H. Kutscher, Lea and Febiger, 1982.


3.            Nelson, E.B., Sweet, C.S., Shahinfar, S., Goldberg, M.R., Medicinal Chemistry of the Renin-Angiotensin System:  Chapter 16. Losartan Potassium:  Current Clinical Status.  Elsevier Science B.V. 1994.


4.            Clinical Profile of the First Angiotensin II (AT-1 Specific) Receptor Antagonists. In:  Hypertension: Physiology, Diagnosis, and Management, Second Edition. Edward B. Nelson, J.H. Laragh and B.M. Brenner, Chapter 174, 1995.




1.             Goldberg, M., Robertson, D.:  Yohimbine:  A pharmacologic probe for study of the adrenoreceptor.  Pharmacological Reviews, 35:143-180, 1983.




1.       Goldberg, M., Joiner, P., Greenberg, S., Hyman, A., Kadowitz, P.:  Effects of indomethacin on venoconstrictor responses to bradykinin and norepinephrine, Prostaglandins, 9:385-390, 1975.


2.       Goldberg, M., Joiner, P., Hyman, A., Kadowitz, P.:  Human greater and canine lateral saphenous veins:  A morphologic and pharmacologic study.  Blood Vessels, 12:89-97, 1975.


3.       Goldberg, M., Joiner, P., Hyman, A., Kadowitz, P.:  Unusual venoconstrictor effects of angiotension ll.  Proc. Soc. Exp. Biol. Med., 149:707-713, 1975.


4.       Goldberg, M., Chapnick, B., Joiner, P., Hyman, A., Kadowitz, P.:  Influence of inhibitors of prostaglandin synthesis on venoconstrictor responses to bradykinin.  J. Pharm. Exp. Therap., 198:357-365, 1976.


5.       Goldberg, M., Hebert, V., Kadowitz, P.:  Effects of prostaglandins and endoperoxide analogs on isolated canine saphenous vein.  American J. Physiology, 233:H361-H368, 1977.


6.       Fink, G.D. Chapnick, B.M., Goldberg, M.R., Paustian, P.W., Kadowitz, P.J.:  Influence of indomethacin and reserpine on renal vascular responses to nerve stimulation, pressor and depressor hormones.  Circ. Res., 41:172-179, 1977.


7.       Goldberg, M.R., Kadowitz, P.J.:  A comparison of the effects of 5- and 6-hydroxydopamine on isolated canine saphenous veins.  Circ. Res., 43:357-364, 1978.


8.       Goldberg, M.R., Robertson, R.M. and Robertson, D.:  Atrial tachypacing in the treatment of orthostatic hypotension.  Letter to Editor, New England Journal of Medicine, 303:885-886, 1980.


9.       Goldberg, M.R., Gerkins, J.F., Oates, J.A., and Robertson, D.:  -methylepinephrine, a methyldopa metabolite that binds to -receptors in rat brain.  Eur. J. Pharmacol., 69:95-99, 1981.


10.     Taylor, C.A., Jr., Smith, H.E., Goldberg, M.R. and Robertson, D.: (S)-erythro--methylepinephrine:  Preparation and stereoselective binding to adrenergic receptors in rat forebrain. J. Medicinal Chemistry, 24:1261-1263, 1981.


11.     Goldberg, M.R., Ring, M.E., Tung, C.S., Oates, J.A., Gerkins, J.F. and Robertson, D.:  Evidence that a-methylepinephrine is an antihypertensive metabolite of methyldopa. Clinical and Experimental Hypertension, 4:595-606, 1982.


12.     Goldberg, M.R., Curatolo, P.W., Tung, C.-S., Robertson, D.:  Caffeine down-regulates ß‑adrenoceptors in rat forebrain, Neuroscience Letters, 31:47-52, 1982.


13.     Goldberg, M.R., Tung, C.-S, Feldman, R.D., Smith, H.E., Oates, J.A. and Robertson, D.: Differential competition by methyldopa metabolites for adrenergic receptors in rat forebrain.  J. Pharm. Exp. Therap., 220:552-560, 1982.


14.     Robertson, D., Goldberg, M.R., Hollister, A.S., Wade, D., and Robertson, R.M.:  Clonidine raises blood pressure in severe idiopathic orthostatic hypotension.  Am. J. Med., 74:193-200, 1983.


15.     Goldberg, M.R., Hollister, A.S., and Robertson, D.:  Influence of yohimbine on blood pressure, autonomic reflexes and plasma catecholamines in humans.  Hypertension, 5:772-778, 1983.


16.     Goldberg, M.R., Tung, C.-S, and Robertson, D.: Influence of -methyldopa treatment on adrenergic receptor binding in rat forebrain.  Clin. Exp. Hypertension, A5:1589-1596, 1983.


17.     Tung, C.-S., Onoura, C.A., Robertson D. and Goldberg. M.R.: Hypertensive effect of yohimbine following selective injection into the nucleus tractus solitarii of normotensive rats.  Brain Res., 277:193-195, 1983.


18.     Tung, C.-S, Goldberg, M.R., Hollister, A.S., Oates, J.A., and Robertson, D.: Central and peripheral cardiovascular effects of -methylepinephrine.  J. Pharmacol. Exp. Ther., 227:484‑490, 1983.


19.     Forman, M.B., Robertson, D., Goldberg, M., Bostick, D., Uderman, H., Perry, J.M. and Robertson, R.M.:  The effect of tyramine on myocardial catecholamine release in man.  Am. J. Cardiol. 53:476-480, 1984.


20.     Goldberg, M.R. and Robertson, D.:  Evidence for the existence of vascular 2 adrenoceptors in man.  Hypertension, 6:551-556, 1984.


21.     Goldberg, M.R., Speier, L.S., Robertson, D.: Yohimbine: Assay by high performance liquid chromatography with electrochemical detection.  J. Liquid Chromatography, 7:1003-1012, 1984.


22.     Parris, W.C.V., Goldberg, M.R., Hollister, A.S., and Robertson, D.:  Anesthetic management in autonomic dysfunction. Anesth. Rev., 11:(Suppl. 6) 17-23, 1984.


23.     Robertson, D., Hollister, A.S., Carey, E.L., Tung, C.-S. and Goldberg, M.R.: Vascular beta-2-adrenoreceptor hypersensitivity in autonomic dysfunction.  J. Am. College Cardiol., 3:850-856, 1984.


24.     Robertson, D., Hollister, A.S., Kincaid, D., Workman, R., Goldberg, M.R., Tung, C.-S, and Smith, B.:  Caffeine and Hypertension.  Am. J. Med. 77:54-60, 1984.


25.     Robertson, D., Tung, C.-S, Goldberg, M.R., Hollister, A.S., Gerkins, J.F., and Oates, J.A.:  Antihypertensive Metabolites of -Methyldopa, Hypertension, 5:(Suppl. II)45-50, 1984.


26.     Ruffolo, Jr., R.R., Goldberg, M.R., And Morgan, E.L.:  Interactions of Epinephrine, Norepinephrine, Dopamine and Their Corresponding -Methyl-Substituted Derivatives with Alpha and Beta Adrenoceptors in the Pithed Rat.  J. Pharmacol. Exp. Ther. 230:595-600, 1984.


27.     Goldberg, M.R., Robertson, D. and Fitzgerald, G.A.: Prostacyclin Biosynthesis and Platelet Function in Autonomic Dysfunction.  Neurology 35:120-123, 1985.


28.     Onrot, J., Goldberg, M.R., Biaggioni, I., Hollister, A.S., Kincaid, D., and Robertson, D.: Hemodynamic and humoral effects of caffeine in autonomic failure. Therapeutic implications for postprandial hypotension.  New Eng. J. Med. 313:549-554, 1985.


29.     Onrot, J., Goldberg, M.R., Hollister, A., Biaggioni, I., Kincaid, D., and Robertson, D.:  Management of Chronic Orthostatic Hypotension.  Am. J. Med. 80:454-464, 1986.


30.     Goldberg, M.R., Jackson, R.V., Krakau, J., Island, D.P., and Robertson, D.: Influence of yohimbine on release of anterior pituitary hormones.  Life Sci. 39:395-398, 1986.


31.     Onrot, J., Shaheen, O., Biaggioni, I., Goldberg, M.R., Feely, J., Wilkinson, G.R., Hollister, A.S., and Robertson, D.:  Reduction of liver plasma flow in man by caffeine and theophylline. Clin. Pharmacol. Ther. 40:506-510, 1986.


32.     Robertson, D., Goldberg, M.R., Onrot, J., Hollister, A.S., Wiley, R., Thompson, J.G., and Robertson, R.M.:  Isolated failure of autonomic noradrenergic neurotransmission: evidence for impaired ß-hydroxylation of dopamine.  New Eng. J. Med. 314:1494-1497, 1986.


33.     Robertson, D., Goldberg, M.R., Tung, C.-S., Hollister, A.S., and Robertson, R.M.:  Use of 2-adrenoreceptor agonists and antagonists in the functional assessment of the sympathetic defect in autonomic failure.  J. Clin. Inv. 78:576-581, 1986.


34.     Onrot, J., Goldberg, M.R., Biaggioni, I., Kincaid, D., Hollister, A.S., and Robertson, D.: Oral yohimbine in human autonomic failure.  Neurology 37:215-220, 1987.


35.     Onrot, J., Goldberg, M.R., Biaggioni, I., Hollister, A.S.:  Postjunctional vascular smooth muscle alpha-2 adrenoreceptors in human autonomic failure.  Clin. Invest. Med. 10:26-31, 1987.


36.     Goldberg, M.R., Sushak, C.S., Rockhold, F.W., Thompson, W.L.:  Vasodilator monotherapy in the treatment of hypertension:  Comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin.  Clin. Pharmacol. Ther. 44:78-92, 1988.


37.     Goldberg, M.R.:  Clinical pharmacology of pinacidil, a prototype for drugs which affect potassium channels. J. Cardiovasc. Pharmacol.  Suppl. 12, 2:S41-S47, 1988.


38.     Tung, C.-S., Goldberg, M. R., Hollister, A. S., Sweetman, B. J., Robertson, D.: Depletion of Brainstem Epinephrine Stores By a-Methyldopa:  Possible Relation to Attenuated Sympathetic Outflow.  Life Sciences 42:2365-2371, 1988.


39.     Callaghan, J.T., Goldberg, M.R., Brunell, R.: Double-blind comparator trials with pinacidil, a potassium channel opener.  Drugs Suppl. 36, 7:77-82, 1988.


40.     Goldberg, M.R., Offen, W.W.: Pinacidil with and without hydrochloro-thiazide: dose-response relationships from results of a 4x3 factorial design study.  Drugs Suppl. 36, 7:83-92, 1988.


41.     Tung, C.S., Goldberg, M.R., Hollister, A.S., Robertson, D.:  Both - and ß-adrenoreceptors contribute to the central depressor effect of catecholamines.  Brain Research 456:64-70, 1988.


42.     Goldberg, M.R., Offen, W.W., Rockhold, F.W.:  Factorial design:  An approach to the assessment of therapeutic drug interactions in hypertension.  J. Clin. Res. Drug Dev. 2:215-225, 1988.


43.     Goldberg, M.R., Rockhold, F.W., Thompson, W.L., DeSante, K.A.: Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.  J Clin Pharmacol. 29:33-40, 1989.


44.     Goldberg, M.R., Rockhold, F.W., Offen, W.W., Dornseif, B.E.:  Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension.  Clin. Pharm. Ther. 46:208-218, 1989.


45.     Rockhold, F.W., Goldberg, M.R., Thompson, W.L., The Pinacidil-Prazosin and Pinacidil-Placebo Research Groups: Beneficial effects of pinacidil on blood lipids:  Comparisons with prazosin and placebo in hypertensive patients.  J. Lab Clin. Med. 114:646-654, 1989.


46.     Warren, J.B., Dollery C.T., Sciberras, D., Goldberg, M.R.:  Assessment of MK-467, a peripheral a2-adrenergic receptor antagonist, with intravenous clonidine.  Clin Pharmacol Ther 50:71-77, 1991.


47.     Corder, C.N., Goldberg, M.R., Alaupovic, P.A., Price, M.D., Furste, S.S.:  Lipid and apolipoprotein levels during therapy with Pinacidil combined with hydrochlorothiazide. European Journal of Clinical Pharmacology 42:65-70, 1992.


48.     Goldberg, M.R., Tanaka, W., Barchowsky, A., Bradstreet, T.E., McCrea, J., Lo, M-W, McWilliams, E.J., Bjornsson, T.D.:  Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.  Hypertension 21(5):704-713, 1993.


49.     Greenberg, H. E., Wissel, P., Barrett, J., Barchowsky, A., Gould, R., Farrell, D., Panebianco, D., Hand, B.S., Gillen, L., Goldberg, M.R., Bjornsson, T. D.  Antiplatelet Effects of MK-852, a Platelet Fibrinogen Receptor Antagonist, in Healthy Volunteers.  J Clin Pharmacol 2000; 496-507.


50.     Ritter, J.M., Cockcroft, J.R., Sciberras, D.G., Goldberg, M.R.:  Clinical pharmacology of angiotensin and bradykinin in human forearm vasculature.  J. of Hypertension 11(suppl 3):S59-S61, 1993.


51.     Cockcroft, J.R., Sciberras, D.G., Goldberg, M.R., Ritter, J.M.:  Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm.  Journal of Cardiovascular Pharmacology, 22:579-584, 1993.


52.     Peerlinck, K., De Lepeleire, I., Goldberg, M., Farrell, D., Barrett, J., Hand, E., Panebianco, D., Deckmyn, H., Vermylen, J., Arnout, J.:  MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 88(4,Part1):1512-1517, 1993.


53.     Sciberras, D.G., Reed, J.W., Elliott, C, Blain, P.G., Goldberg, M.R.:  The effects of a peripherally selective 2-antagonist, MK-467, on the metabolic and cardiovascular response to exercise in healthy man. Br Journal Clin. Pharmac. 37:39-44, 1994.


54.     Goldberg, M.R., Bradstreet, T.E., McWilliams, E.J., Tanaka, W.K., Lipert, S., Bjornsson, T.D., Waldman, S.A., Osborne, B., Pivadori, L., Lewis, G., Blum, R., Herman, T., Abraham, P.A., Halstenson, C.N., Lo, M-W., Lu, H., Spector, R.:  Biochemical effects of losartan, a non-peptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 25(vol 1):37-46, 1995.


55.     Kong, A-N.T, Tomasko, L., Waldman, S.A., Osborne, B., Deutsch, P.J., Goldberg, M.R., Bjornsson, T.D.:  Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 35:1008-1015, 1995.


56.     Goldberg, M.R., Lo, M-W., Bradstreet, T.E., Ritter, M.A., Höglund, P.:  Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. Eur J Clin Pharmacol 49:115-119, 1995.


57.     Goldberg, M.R., Heimbrook, D.C., Russo, P., Sarosdy, M.F., Greenberg, R.E., Giantonio, B.J., Linehan, W.M., Walther, M., Fisher, H.A.G., Messing, E., Crawford, E.D., Oliff, A.I., Pastan, I.H.:  Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer.  Clinical Cancer Research 1:57-61, 1995.


58.     Siegl, P., Goldberg, M.R.:  Epidemiology and cardiovascular drug discovery through the 1990s.  Exp. Opin. Invest. Drugs 4:345-347, 1995.


59.     Opsahl, J.A., Goldberg, M.R., Katz, S.A.:  Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms.  American Journal of Hypertension, Ltd. 8:1090-1098, 1995.


60.     Lo, M-W, Goldberg, M.R., McCrea, J.B., Lu, H., Furtek, C.I., Bjornsson, T.D.:  Pharmacokinetics of losartan, an angiotensin II receptor antagonist and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58:641-649, 1995.


61.     McCrea, J.B., Lo, M-W, Tomasko, L., Lin, C., Hsieh, JY-K, Capra, N., Goldberg, M.R.:  Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide.  J Clin Pharmacol 35:1200-1206, 1995.


62.     De Smet, M., Schoors, D.F., De Meyer, G., Verbesselt, R., Goldberg, M.R., Fitzpatrick, V., Somers, G.:  Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers.  Br J Clin Pharmacology 40:571-575, 1995.


63.     Goldberg, M.R., Lo, M-W, Deutsch, P.J., Wilson, S.E., McWilliams, E.J., McCrea, J.B.:  Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite, E-3174.  Clin Pharmacol Ther 59: 268-274, 1996.


64.     Goldberg, M.R., de Mey, C., Wroblewski, M.S., Li, Q., Schroeter, V., Belz, G.G.:  Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men.  Clin Pharmacol Ther 59:72-82, 1996.


65.     Wexler, R.R., Greenlee, W.J., Irvin, J.D., Goldberg, M.R., Prendergast, K., Smith, R.D., Timmermans, P.:  Nonpeptide angiotensin II receptor antagonists:  The Next Generation in Antihypertensive Therapy.  Journal of Medicinal Chemistry 39:625-656, 1996.


66.     Goldberg, M.R., Lo, M-W, Christ, D.D., Chiou, R, Furtek, C.I., Amit, O., Carides, A., Biollaz, J., Piguet, V., Nussberger, J., Brunner, H.R.: DuP 532, an angiotensin II receptor antagonist:  first administration and comparison with losartan. Clin Pharmacol Ther 61:59-69, 1997.


67.     Lee, Y., Ermlich, S., Sterrett, A.T., Goldberg, M.R., Blum, R.A., Brucker, M.J., McLoughlin, D.A., Olah, T.V., Zhao, J., Rogers, J.D.  Pharmacokinetics and Tolerability of Intravenous Rizatriptan in Healthy Females.  Biopharm. Drug Dispos. 19:577-581, 1998.


68.     Goldberg, M.R., Lowry, R.C., Musson, D.G., Birk, K.L., Fisher, A., DePuy, E., Shadle, C.R.  Lack of Pharmacokinetic and Pharmacodynamic Interaction between Rizatriptan and Paroxetine.  J Clin Pharmacol 39:192-199, 1999.


69.     McCrea J.B., Cribb A, Rushmore T, Osborne B, Gillen L, Lo M-W, Waldman S, Bjornsson T, Spielberg S, Goldberg M.  Phenotypic and Genotypic Investigations of a Healthy Volunteer Deficient in the Conversion of Losartan to its Active Metabolite E‑3174.  Clin Pharmacol Ther 1999; 65:348-352.


70.     Cutler, N.R., Jhee, S.S., Majumdar, A.K., McLoughlin, D., Brucker, M.J., Carides, A.D., Kramer, M.S., Matzura-Wolfe, D., Reines, S.A., Goldberg, M.R.:  Pharmacokinetics of Rizatriptan Tablets During and Between Migraine Attacks.  Headache 1999; 39:264-269.


71.     van Haarst, A.D., van Gerven, M.A., Cohen, A.F., De Smet, M., Sterrett, A., Birk, K.L., Fisher, A.L., De Puy, M.E., Goldberg, M.R., Musson, D. G.:  The effects of moclobemide on the pharmacokinetics of the 5-HT1B/ID agonist rizatriptan in healthy volunteers.  J Clin Pharmacol 1999; 48:190-196.


72.     Goldberg, M.R., Lee, Y, Vyas, K.P., Slaughter, D.E., Panebianco, D., Ermlich, S.J., Shadle, C.R., Brucker, M.J., McLoughlin, D.A., Olah, T.V.  Rizatriptan, a Novel 5-HT1B/1D Agonist for Migraine:  Single- and Multiple-Dose Tolerability and Pharmacokinetics in Healthy Subjects.  J Clin Pharmacol 2000; 40:74-83.


73.     Shadle, C. R., Liu, G., Goldberg, M.R.  A Double-Blind, Placebo-Controlled Evaluation of the Effect of Oral Doses of Rizatriptan 10 mg on Oral Contraceptive Pharmacokinetics in Healthy Female Volunteers.  J Clin Pharmacol 2000; 40:309-315. 75.


74.     Goldberg, M.R., Sciberras, D., De Smet, M., Lowry, R., Tomasko, L., Lee, Y., Olah, T.V., Zhao, J., Vyas, K.P., Halpin, R., Kari, P.H., James, I.  Influence of beta adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist:  Differential effects of propranolol, nadolol and metoprolol.  British J. Clinical Pharmacol 2001; 52:69-76.


75.     Strachan, F.E., Newby, D.E., Sciberras, D.G., McCrea, J.B., Goldberg, M.R., Webb, D.J.  Repeatability of local forearm vasoconstriction to endothelin-1 measured by venous occlusion plethysmography.  British J. Clinical Pharmacol 2002; 54:386-394.


76.     Feuring, M., Lee, Y., Orlowski, L.H., Michiels, N., De Smet, M., Majumdar, A.K., Petty, K.J., Goldberg, M.R., Murphy, M.G., Gottesdiener, K.M., Hesney, M., Brackett, L.E., Wehling, M.  Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects.  J Clin Pharmacol 43:  912‑917 (2003).


77.     McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, Hesney M, Lines CR, Petty KJ, Deutsch PJ, Murphy GM, Gottesdiener KM, Goldwater R, Blum RA.  Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.  Clin Pharmacol Ther 74(1):  17-24 (2003).


78.     Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, Van Buren S, Waldman SA, Greenberg HE.  Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.  Clin Ther 25(5):  1407-1419 (2003).


79.     Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, Goldberg MR, Murphy G, Gottesdiener KM, Lines CR, Petty KJ, Blum RA.  Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe.  Clin Pharmacol Ther 74(2):  150-156 (2003).


80.     Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg P, Crumley TM, Panebianco D, Bradstreet TE, Bergman AJ, Waldman SA, Greenberg HE, Butler K, Knops A, De Lepeleire I, Michiels N, Petty KJ.  Pharmacokinetics of aprepitant after single and multiple doses in healthy volunteers.  J Clin Pharmacol in Press (2005).


81.     Jacqueline B. McCrea, Anup K. Majumdar, Michael R. Goldberg, Marian Iwamoto, Cynthia Gargano, Deborah L. Panebianco, Michael Hesney, Christopher R. Lines, Kevin J. Petty, Paul J. Deutsch, M. Gail Murphy, Keith M. Gottesdiener, D. Ronald Goldwater, Robert A. Blum, Christopher R. Lines, PhD.  Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.  Clinical Pharmacology & Therapeutics 74, 17 – 24.


82.     Y. Lee, L. H. Orlowski, N. Michiels, K. J. Petty, M. R. Goldberg, J. Dru, C. M. Chavez-Eng, M. Constanzer, G. Murphy, K. Gottesdiener, M. Hesney, M. Feuring, M. Wehling.  Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects.  Clinical Pharmacology & Therapeutics 73, P66 - P66.


83.     M. Iwamoto, J. McCrea, K.E. Mazina, A. Majumdar, C. Gargano, M. Hesney, D.R. Goldwater, K.J. Petty, P.J. Deutsch, K. Gottesdiener.  Increase in methylprednisolone systemic exposure following coadministration with aprepitant.  Clinical Pharmacology & Therapeutics 73, P5 - P5.


84.     J. McCrea, A. Majumdar, J. Busillo, D. Panebianco, M.R. Goldberg, G. Murphy, K. Gottesdiener, M. Hesney, C. Lates, R. Blum.  Pharmacokinetics of dexamethasone when given with aprepitant.  Clinical Pharmacology & Therapeutics 73, P5 - P5.


85.     J. McCrea, A. Majumdar, J. Busillo, D. Panebianco, M.R. Goldberg, G. Murphy, K. Gottesdiener, M. Hesney, C. Lates, R. Blum.  Lack of effect of aprepitant on the pharmacokinetics of ondansetron.  Clinical Pharmacology & Therapeutics 73, P6 - P6.


86.     K.J. Petty, A. Majumdar, L.H. Orlowski, D. Panebianco, M. Hesney, M.R. Goldberg, G. Murphy, K. Gottesdiener, W.K. Kraft, S. Van Buren, S.A. Waldman, H.E. Greenberg.  Lack of effect of aprepitant on the pharmacokinetics of granisetron.  Clinical Pharmacology & Therapeutics 73, P6 - P6.


87.     A. Majumdar, J. McCrea, J. Busillo, D. Panebianco, J. Dru, M. Constanzer, M.R. Goldberg, G. Murphy, K. Gottesdiener, R. Blum, C. Lates.  Evaluation of the effect of aprepitant on CYP3A4 activity using midazolam as a probe.  Clinical Pharmacology & Therapeutics 73, P6 - P6.


88.     Anup K. Majumdar, Laura Howard, Michael R. Goldberg, Lisa Hickey, Marvin Constanzer, Paul L. Rothenberg, Tami M. Crumley, Deborah Panebianco, Thomas E. Bradstreet, Arthur J. Bergman, Scott A. Waldman, Howard E. Greenberg, Kathleen Butler, A. Knops, Inge De Lepeleire, Nicole Michiels, and Kevin J. Petty.  Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers.  J. Clin. Pharmacol., Mar 2006; 46: 291 – 300.


89.     Bergstrom M. Hargreaves RJ. Burns HD. Goldberg MR. Sciberras D. Reines SA. Petty KJ. Ogren M. Antoni G. Langstrom B. Eskola O. Scheinin M. Solin O. Majumdar AK. Constanzer ML. Battisti WP. Bradstreet TE. Gargano C. Hietala J. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biological Psychiatry. 55(10):1007-12, 2004.


90.             Hietala J, Nyman MJ, Eskola O, Laakso A, Tove Gronroos T, Oikonen V, Bergman J, Haaparanta M, Forsback S, Marjamaki P, Lehikoinen P, Goldberg M, Burns D, Hamill T, Eng W-S, Coimbra A, Hargreaves R, Solin S.  Visualization and Quantification of Neurokinin-1 (NK1) Receptors in the Human Brain, 2005, Mol Imaging Biol 7:262–272


91.     Gotfried MH, Shaw JP, Benton BM, Krause KM, Goldberg MR, Kitt MM, Barriere SL.   Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics, 2008;  Antimicrob Agents Chemother. 52:92-7


92.     Wong SL, Barriere SL, Kitt MM, Goldberg MR.  Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.  J Antimicrob Chemother., 2008; 62:780-3.


93.     Wong S, Goldberg MR, Kitt MM, Barriere S, Lack of a Pharmacokinetic Interaction following Concomitant Administration of Telavancin with either Aztreonam or Piperacillin/Tazobactam in Healthy Subjects.  J Clin Pharmacol. 2009 49:816-23.


94.     Goldberg M, Wong SL, Shaw JP, Kitt M, Barriere S, Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin, 2010, Pharmacotherapy. 30:35-42


95.     Gotfried MH, Shaw JP, Benton BM, Krause KM, Goldberg MR, Kitt MM, Barriere SL. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008 52:92-7


96.     Shaw JP, Cheong J, Goldberg M, and Kitt M. Mass Balance and Pharmacokinetics of [14C]Telavancin Following Intravenous Administration to Healthy Male Volunteers, Antimicrob Agents Chemother. 2010 54:3365-71


97.     Goldberg MR, Wong SL, Shaw JP, Barriere SL, Kitt MM, Single-dose pharmacokinetics of telavancin in elderly men and women Pharmacotherapy, 2010, 30:806-811


98.     Wong SL, Goldberg MR, Ballow CH, Kitt MM, Barriere SL. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy. 2010 30:136-43


99.     Barriere SL, Goldberg MR, Janc JW, Higgins DL, Macy PA, Adcock DM. Effects of telavancin on coagulation test results. Int J Clin Pract. 2011 65:784-9


100.  Lehman HP, Chen J, Gould AL, Kassekert R, Beninger PR, Carney R, Goldberg M, Goss MA, Kidos K, Sharrar RG, et al.  An Evaluation of Computer-Aided Disproportionality Analysis for Post-Marketing Signal Detection  Clinical Pharmacology & Therapeutics; 2007; 82:173-180.


101.  Goldberg M, Li Y-P, Johanson JF, Mangel AW, Kitt M, Beattie DT, Kersey K, Daniels O.  Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4-week, randomized, double-blind, placebo-controlled, dose–response study.  Aliment Pharmacol Ther; 2010; 32:1102–1112


102.  Manini ML, Camilleri M, Goldberg M, Sweetser S, Mckinzie S, Burton D, Wong S, Kitt MM, Li Y-P, Zinsmeister AR.   Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation.  Neurogastroenterol Motil.  2010; 22, 42–50







1.       Pinacidil Comparative Trials:  Summary of Safety Results.  Pinacidil Investigator Symposium:  Results of Clinical Trials in Hypertension, Arlington, VA, November 9, 1985.


2.       A proposed study design for evaluating fixed-combinations in hypertension. U.S. Food and Drug Administration, Cardio-Renal Advisory Committee, Bethesda, MD, December 17, 1985.


3.       Pinacidil: Summary of Efficacy Results. U.S. Food and Drug Administration, Cardio-Renal Advisory Committee, Bethesda, MD, May 27, 1987.


4.       Pinacidil: Summary of Safety Results. U.S. Food and Drug Administration, Cardio-Renal Advisory Committee, Bethesda, MD, May 27, 1987.


5.       Factorial designs in the development of fixed combinations of antihypertensive drugs. Workshop on Guidelines for the Clinical Assessment of Antihypertensive Drugs.  Hypertension Council, American Heart Association, Pharmaceutical Manufacturers Association, U.S. Food and Drug Administration, Cardio-Renal Division, Crystal City, VA, June 1-2, 1987.


6.       Clinical Pharmacology of Drugs which affect Potassium Channels.  Pinacidil - the Role of Potassium Channels in Vascular Relaxation.  Lilly Research Laboratories, Indianapolis, IN, June 26, 1987.






U. S. Patent No. 5,817,658, 1998, Method for Treating Meniere’s Disease



April 13, 2017